JP2018510881A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018510881A5 JP2018510881A5 JP2017550603A JP2017550603A JP2018510881A5 JP 2018510881 A5 JP2018510881 A5 JP 2018510881A5 JP 2017550603 A JP2017550603 A JP 2017550603A JP 2017550603 A JP2017550603 A JP 2017550603A JP 2018510881 A5 JP2018510881 A5 JP 2018510881A5
- Authority
- JP
- Japan
- Prior art keywords
- therapeutic agent
- agent according
- cells
- monoclonal antibody
- combined therapeutic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562139258P | 2015-03-27 | 2015-03-27 | |
| US62/139,258 | 2015-03-27 | ||
| PCT/US2016/024318 WO2016160602A2 (en) | 2015-03-27 | 2016-03-25 | Genetically modified nk-92 cells and monoclonal antibodies for the treatment of cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020133495A Division JP7000512B2 (ja) | 2015-03-27 | 2020-08-06 | がん治療のための遺伝子改変ｎｋ－９２細胞およびモノクローナル抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018510881A JP2018510881A (ja) | 2018-04-19 |
| JP2018510881A5 true JP2018510881A5 (enExample) | 2019-05-09 |
| JP6748105B2 JP6748105B2 (ja) | 2020-08-26 |
Family
ID=57006343
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017550603A Active JP6748105B2 (ja) | 2015-03-27 | 2016-03-25 | がん治療のための遺伝子改変ｎｋ−９２細胞およびモノクローナル抗体 |
| JP2020133495A Active JP7000512B2 (ja) | 2015-03-27 | 2020-08-06 | がん治療のための遺伝子改変ｎｋ－９２細胞およびモノクローナル抗体 |
| JP2021208864A Active JP7328314B2 (ja) | 2015-03-27 | 2021-12-23 | がん治療のための遺伝子改変ｎｋ－９２細胞およびモノクローナル抗体 |
| JP2023126658A Active JP7557704B2 (ja) | 2015-03-27 | 2023-08-03 | がん治療のための遺伝子改変ｎｋ－９２細胞およびモノクローナル抗体 |
| JP2024146060A Active JP7766151B2 (ja) | 2015-03-27 | 2024-08-28 | がん治療のための遺伝子改変ｎｋ－９２細胞およびモノクローナル抗体 |
| JP2025180073A Pending JP2026021400A (ja) | 2015-03-27 | 2025-10-27 | がん治療のための遺伝子改変ｎｋ－９２細胞およびモノクローナル抗体 |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020133495A Active JP7000512B2 (ja) | 2015-03-27 | 2020-08-06 | がん治療のための遺伝子改変ｎｋ－９２細胞およびモノクローナル抗体 |
| JP2021208864A Active JP7328314B2 (ja) | 2015-03-27 | 2021-12-23 | がん治療のための遺伝子改変ｎｋ－９２細胞およびモノクローナル抗体 |
| JP2023126658A Active JP7557704B2 (ja) | 2015-03-27 | 2023-08-03 | がん治療のための遺伝子改変ｎｋ－９２細胞およびモノクローナル抗体 |
| JP2024146060A Active JP7766151B2 (ja) | 2015-03-27 | 2024-08-28 | がん治療のための遺伝子改変ｎｋ－９２細胞およびモノクローナル抗体 |
| JP2025180073A Pending JP2026021400A (ja) | 2015-03-27 | 2025-10-27 | がん治療のための遺伝子改変ｎｋ－９２細胞およびモノクローナル抗体 |
Country Status (10)
| Country | Link |
|---|---|
| US (6) | US10456420B2 (enExample) |
| EP (1) | EP3273993A4 (enExample) |
| JP (6) | JP6748105B2 (enExample) |
| KR (3) | KR102751730B1 (enExample) |
| CN (4) | CN113604435A (enExample) |
| AU (3) | AU2016243120B2 (enExample) |
| CA (1) | CA2977423A1 (enExample) |
| HK (2) | HK1249854A1 (enExample) |
| IL (4) | IL294982B2 (enExample) |
| WO (1) | WO2016160602A2 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113604435A (zh) * | 2015-03-27 | 2021-11-05 | 南克维斯特公司 | 用于治疗癌症的被遗传修饰的nk-92细胞和单克隆抗体 |
| EP3458485B1 (en) | 2016-05-19 | 2021-12-29 | The General Hospital Corporation | Tethered interleukin-2 to its receptor il-2rbeta, a platform to enhance natural killer and regulatory t cell activity |
| CA3042238C (en) * | 2016-10-28 | 2021-08-10 | Nant Holdings Ip, Llc | Avatar dendritic cells: the neoantigen natural killer t-cell chemo immuno radiation composition inducing immunogenic cell death |
| US20180221463A1 (en) * | 2017-01-13 | 2018-08-09 | The Chinese University Of Hong Kong | Modified NK Cells and Uses Thereof |
| AU2018231193B2 (en) * | 2017-03-08 | 2021-07-22 | Immunitybio, Inc. | Modified NK-92 haNK003 cells for the clinic |
| KR20200015469A (ko) * | 2017-05-11 | 2020-02-12 | 난트케이웨스트, 인크. | 항-egfr/고친화성 nk-세포 조성물 및 척색종 치료 방법 |
| WO2019036485A1 (en) | 2017-08-15 | 2019-02-21 | Nantcell, Inc. | ASSOCIATIONS OF CÉTUXIMAB AND HIGH AFFINITY NATURAL KILLER CELLS AND ASSOCIATED METHODS |
| US20190321402A1 (en) * | 2018-04-19 | 2019-10-24 | Onkimmune Limited | Nk cells for use with anitbodies in cancer therapy |
| CN108531458A (zh) * | 2018-04-27 | 2018-09-14 | 赛诺（深圳）生物医药研究有限公司 | 治疗肿瘤的基因工程自然杀伤细胞产品 |
| WO2020014245A1 (en) | 2018-07-10 | 2020-01-16 | Nantkwest, Inc. | Cryopreservation |
| JP7241161B2 (ja) | 2018-08-01 | 2023-03-16 | イミュニティーバイオ、インコーポレイテッド | 細胞免疫療法の安定した遺伝子改変のための、ホーミング受容体又はサイトカインとキメラ抗原受容体とを含むクアドリシストロニックシステム |
| US12098177B2 (en) | 2018-09-07 | 2024-09-24 | Nantbio, Inc. | Targeted IL-12 treatments and methods to stimulate haNK and NK92mi cells |
| CN112292448B (zh) * | 2018-10-31 | 2025-01-10 | 南克维斯特公司 | 表达cd19-car的nk细胞消除cd19阳性淋巴系统恶性肿瘤 |
| US11077143B2 (en) * | 2018-10-31 | 2021-08-03 | Nantkwest Inc. | Elimination of PD-L1-positive malignancies by PD-L1 chimeric antigen receptor-expressing NK cells |
| CA3117936A1 (en) * | 2018-11-26 | 2020-06-04 | Immunitybio, Inc. | Il-2 dependent nk-92 cells with stable fc receptor expression |
| CN119040363A (zh) * | 2019-03-15 | 2024-11-29 | 河谷细胞有限公司 | 重组erIL-15 NK细胞 |
| US12085571B2 (en) | 2019-06-13 | 2024-09-10 | Immunitybio, Inc. | Biological deposit labeling and tracking including isotope, rare earth metal or mitochondria tags |
| CN114269377A (zh) * | 2019-07-26 | 2022-04-01 | 南克维斯特公司 | 作为用于肿瘤溶解的有效治疗性产品的抗体预加载cd16+nk-92细胞 |
| CN115190910A (zh) * | 2019-11-20 | 2022-10-14 | 免疫生物公司 | 细胞介导的免疫增强分子到肿瘤微环境中的瞬时递送 |
| WO2021116913A1 (en) * | 2019-12-09 | 2021-06-17 | Nantkwest, Inc. | Screening of cell clones expressing polygenic transgenes through non-antibiotic dependent positive selection |
| US11230699B2 (en) | 2020-01-28 | 2022-01-25 | Immunitybio, Inc. | Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors |
| TW202237827A (zh) | 2020-12-03 | 2022-10-01 | 美商世紀治療股份有限公司 | 經基因工程改造之細胞及其用途 |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| CN116635064A (zh) | 2020-12-18 | 2023-08-22 | 世纪治疗股份有限公司 | 具有适应性受体特异性的嵌合抗原受体系统 |
| AU2022224066A1 (en) * | 2021-02-19 | 2023-09-07 | Angeles Therapeutics, Inc. | Single-chain and multi-chain synthetic antigen receptors for diverse immune cells |
| CN116948012B (zh) * | 2022-04-13 | 2024-07-26 | 星奕昂(上海)生物科技有限公司 | 增强细胞功能的cd16抗剪切突变体 |
| WO2024064824A2 (en) | 2022-09-21 | 2024-03-28 | Yale University | Compositions and methods for identification of membrane targets for enhancement of nk cell therapy |
| WO2025158400A1 (en) | 2024-01-24 | 2025-07-31 | Yale University | Compositions and methods of natural killer cell hyperboosts for enhancement of nk cell therapy |
| US20250298030A1 (en) * | 2024-03-20 | 2025-09-25 | Immunitybio, Inc. | Compositions and Methods for NK-92 Cells Expressing Native CD16 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8034332B2 (en) | 1997-04-30 | 2011-10-11 | Conkwest, Inc. | Interleukin-secreting natural killer cell lines and methods of use |
| DE69834257T2 (de) | 1997-04-30 | 2007-01-04 | Klingemann, Hans | Natürliche killerzelllinien und verfahren zu ihrer verwendung |
| US7583797B2 (en) * | 2000-07-10 | 2009-09-01 | Broadcom Corporation | Single ended analog front end |
| EP1513554B9 (en) * | 2002-05-30 | 2011-11-09 | Macrogenics, Inc. | Cd16a binding proteins and use for the treatment of immune disorders |
| WO2006004518A1 (en) * | 2004-07-02 | 2006-01-12 | Avaris Ab | Method for the genetic activation of cells and uses of said cells |
| EP2801583B1 (en) | 2004-07-10 | 2018-04-25 | Fox Chase Cancer Center | Genetically modified human natural killer cell lines |
| EP2161339A1 (en) * | 2008-08-29 | 2010-03-10 | F. Hoffmann-La Roche Ag | ADCC with modified NK92 cells |
| BR112017000497B1 (pt) * | 2014-07-11 | 2023-12-26 | Ventana Medical Systems, Inc | Anticorpo isolado, célula hospedeira procariótica, imunoconjugado e método de detecção da presença ou do nível de expressão de pd-l1 |
| US9078488B1 (en) * | 2014-09-30 | 2015-07-14 | Nike, Inc. | Article of footwear incorporating a lenticular knit structure |
| CN113604435A (zh) * | 2015-03-27 | 2021-11-05 | 南克维斯特公司 | 用于治疗癌症的被遗传修饰的nk-92细胞和单克隆抗体 |
-
2016
- 2016-03-25 CN CN202110908609.9A patent/CN113604435A/zh active Pending
- 2016-03-25 CN CN202311097228.2A patent/CN117379460A/zh active Pending
- 2016-03-25 HK HK18109327.5A patent/HK1249854A1/zh unknown
- 2016-03-25 US US15/529,848 patent/US10456420B2/en active Active
- 2016-03-25 HK HK18106805.2A patent/HK1247117A1/zh unknown
- 2016-03-25 IL IL294982A patent/IL294982B2/en unknown
- 2016-03-25 KR KR1020227036402A patent/KR102751730B1/ko active Active
- 2016-03-25 IL IL254214A patent/IL254214B2/en unknown
- 2016-03-25 CA CA2977423A patent/CA2977423A1/en active Pending
- 2016-03-25 CN CN201680019087.4A patent/CN107427578A/zh active Pending
- 2016-03-25 KR KR1020177030593A patent/KR102460387B1/ko active Active
- 2016-03-25 KR KR1020257000202A patent/KR20250009013A/ko active Pending
- 2016-03-25 EP EP16773863.2A patent/EP3273993A4/en active Pending
- 2016-03-25 CN CN202210150391.XA patent/CN114533867A/zh active Pending
- 2016-03-25 AU AU2016243120A patent/AU2016243120B2/en active Active
- 2016-03-25 JP JP2017550603A patent/JP6748105B2/ja active Active
- 2016-03-25 IL IL301331A patent/IL301331A/en unknown
- 2016-03-25 WO PCT/US2016/024318 patent/WO2016160602A2/en not_active Ceased
- 2016-03-25 IL IL287051A patent/IL287051B/en unknown
-
2019
- 2019-08-15 US US16/541,847 patent/US10736921B2/en active Active
-
2020
- 2020-06-17 US US16/903,882 patent/US11000550B2/en active Active
- 2020-08-06 JP JP2020133495A patent/JP7000512B2/ja active Active
-
2021
- 2021-03-30 US US17/217,839 patent/US11207350B2/en active Active
- 2021-11-09 AU AU2021266225A patent/AU2021266225B2/en active Active
- 2021-11-18 US US17/530,211 patent/US12384852B2/en active Active
- 2021-12-23 JP JP2021208864A patent/JP7328314B2/ja active Active
-
2023
- 2023-08-03 JP JP2023126658A patent/JP7557704B2/ja active Active
-
2024
- 2024-08-28 JP JP2024146060A patent/JP7766151B2/ja active Active
-
2025
- 2025-04-11 AU AU2025202587A patent/AU2025202587A1/en active Pending
- 2025-07-17 US US19/272,876 patent/US20250340664A1/en active Pending
- 2025-10-27 JP JP2025180073A patent/JP2026021400A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018510881A5 (enExample) | ||
| Hou et al. | Navigating CAR-T cells through the solid-tumour microenvironment | |
| Raghani et al. | Revolutionizing cancer treatment: comprehensive insights into immunotherapeutic strategies | |
| Ochoa et al. | Antibody‐dependent cell cytotoxicity: immunotherapy strategies enhancing effector NK cells | |
| CN107709548B (zh) | 用于增强治疗性免疫细胞的功效的方法 | |
| EP2513146B1 (en) | Antibodies against ror1 capable of inducing cell death of cll | |
| Bhojwani et al. | Relapsed childhood acute lymphoblastic leukaemia | |
| JP2018500006A5 (enExample) | ||
| JP2018517415A5 (enExample) | ||
| JP2019511222A5 (enExample) | ||
| JP2017506217A5 (enExample) | ||
| JP2016520074A5 (enExample) | ||
| RU2021114500A (ru) | НАПРАВЛЕННОЕ ИНГИБИРОВАНИЕ TGFβ | |
| JP2009541492A5 (enExample) | ||
| JP2019507582A5 (enExample) | ||
| IL303269A (en) | Genetically engineered cells and uses thereof | |
| JP2014528696A (ja) | 前立腺特異幹細胞抗原に対する抗体およびその使用 | |
| TW201110981A (en) | Combination therapy of an afucosylated CD20 antibody with fludarabine and/or mitoxantrone | |
| CA3189137A1 (en) | Methods and compositions for stimulating gamma delta t cells | |
| EP3291833A1 (en) | Nk cells and antibodies for cancer treatment | |
| JP2018506287A5 (enExample) | ||
| Danhof et al. | CARs and other T cell therapies for MM: the clinical experience | |
| Schultz et al. | New developments in immunotherapy for pediatric solid tumors | |
| JP7148399B2 (ja) | 悪性疾患に対する併用療法 | |
| CN104288765A (zh) | 一种利用具有中和FLT3生物学活性的McAb应用于肿瘤的靶向治疗的新方法 |